دورية أكاديمية
Intraosseous Spindle Cell Rhabdomyosarcoma with MEIS1 :: NCOA2 Fusion - Case Report with Substantial Clinical Follow-up and Review of the Literature.
| العنوان: | Intraosseous Spindle Cell Rhabdomyosarcoma with MEIS1 :: NCOA2 Fusion - Case Report with Substantial Clinical Follow-up and Review of the Literature. |
|---|---|
| المؤلفون: | Smith BF; Department of Pathology and Laboratory Medicine, Oregon Health & Science University, Portland, OR, USA., Doung YC; Department of Orthopaedics and Rehabilitation, Oregon Health & Science University, Portland, OR, USA., Beckett B; Department of Diagnostic Radiology, Oregon Health & Science University, Portland, OR, USA., Corless CL; Department of Pathology and Laboratory Medicine, Oregon Health & Science University, Portland, OR, USA.; Knight Diagnostic Laboratories, Oregon Health & Science University, Portland, OR, USA., Davis LE; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA., Davis JL; Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA. |
| المصدر: | Cancer investigation [Cancer Invest] 2023 Sep; Vol. 41 (8), pp. 704-712. Date of Electronic Publication: 2023 Sep 06. |
| نوع المنشور: | Review; Case Reports; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 8307154 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-4192 (Electronic) Linking ISSN: 07357907 NLM ISO Abbreviation: Cancer Invest Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2015- : Abingdon, Oxford : Taylor & Francis Original Publication: [New York, N.Y. : Marcel Dekker, c1983- |
| مواضيع طبية MeSH: | Transcription Factors*/genetics , Rhabdomyosarcoma*/genetics , Rhabdomyosarcoma*/therapy , Rhabdomyosarcoma*/pathology, Adult ; Humans ; Child ; Follow-Up Studies ; Nuclear Receptor Coactivator 2/genetics ; DNA-Binding Proteins/genetics |
| مستخلص: | Spindle cell/sclerosing rhabdomyosarcoma (SSRMS) is a clinicopathologically and molecularly heterogeneous disease. Gene fusions have been identified in intraosseous SSRMS, consisting predominantly of EWSR1 / FUS :: TFCP2 and MEIS1 :: NCOA2 . The former often follow an aggressive clinical course; there is limited clinical follow-up available for the latter. We report here a new case of the very rare intraosseous SSRMS with MEIS1 :: NCOA2 gene fusion and include the detailed treatment course and 52 months of clinical follow-up. SSRMS with MEIS1 :: NCOA2 gene fusion appears biologically distinct from other intraosseous SSRMS, following a course characterized by local recurrence with rare reports of metastasis to date. |
| التعليقات: | Erratum in: Cancer Invest. 2023 Sep;41(8):750. (PMID: 37733418) |
| فهرسة مساهمة: | Keywords: MEIS1; NCOA2; Rhabdomyosarcoma; bone; gene fusion |
| المشرفين على المادة: | 0 (Transcription Factors) 0 (NCOA2 protein, human) 0 (Nuclear Receptor Coactivator 2) 0 (TFCP2 protein, human) 0 (DNA-Binding Proteins) |
| تواريخ الأحداث: | Date Created: 20230905 Date Completed: 20231101 Latest Revision: 20231101 |
| رمز التحديث: | 20240829 |
| DOI: | 10.1080/07357907.2023.2255668 |
| PMID: | 37668330 |
| قاعدة البيانات: | MEDLINE |
PDF full text from Publisher | تدمد: | 1532-4192 |
|---|---|
| DOI: | 10.1080/07357907.2023.2255668 |